Amgen: ABP 215 Shows Clinical Equivalence To Bevacizumab In Phase 3 Study

(RTTNews) - Amgen (AMGN) and Allergan plc. (AGN) announced a Phase 3 study of biosimilar candidate ABP 215 met its primary and secondary endpoints. The study evaluated the efficacy and safety of ABP 215 compared with Avastin in adult patients with advanced non-squamous non-small cell lung cancer. The company said the primary endpoint, an assessment of objective response rates, was within the prespecified margin for ABP 215 compared to bevacizumab, showing clinical equivalence.

Safety and immunogenicity of ABP 215 were comparable to bevacizumab. Secondary endpoint results were consistent with the primary finding.

Amgen and Allergan are collaborating on the development and commercialization of four oncology biosimilars. Amgen has a total of nine biosimilars in development. Allergan is also independently developing biosimilars.